IHE Holdings — iShares U.S. Pharmaceuticals ETF
All 59 reported holdings of iShares U.S. Pharmaceuticals ETF (IHE) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Johnson & Johnson | 23.03% | $230.42M |
| Eli Lilly And Company | 21.06% | $210.71M |
| Merck & Co., Inc. | 4.74% | $47.42M |
| Pfizer Inc. | 4.71% | $47.12M |
| Royalty Pharma PLC | 4.70% | $47.07M |
| Bristol-Myers Squibb Company | 4.63% | $46.32M |
| Zoetis Inc. | 4.52% | $45.21M |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 4.36% | $43.58M |
| Viatris Inc. | 4.35% | $43.49M |
| Elanco Animal Health Incorporated | 3.32% | $33.23M |
| Jazz Pharmaceuticals Public Limited Company | 3.21% | $32.11M |
| Axsome Therapeutics, Inc. | 2.00% | $20.01M |
| Terns Pharmaceuticals Inc | 1.27% | $12.68M |
| Ligand Pharmaceuticals Incorporated | 1.10% | $10.98M |
| Indivior Pharmaceuticals, Inc. | 1.06% | $10.64M |
| Corcept Therapeutics Incorporated | 1.05% | $10.55M |
| Crinetics Pharmaceuticals Inc | 1.04% | $10.41M |
| Supernus Pharmaceuticals, Inc. | 0.83% | $8.28M |
| Prestige Consumer Healthcare Inc. | 0.78% | $7.84M |
| Tarsus Pharmaceuticals Inc | 0.77% | $7.66M |
| Liquidia Corp | 0.72% | $7.25M |
| Edgewise Therapeutics Inc | 0.65% | $6.52M |
| Amneal Pharmaceuticals, Inc. | 0.59% | $5.90M |
| Nektar Therapeutics | 0.56% | $5.63M |
| Definium Therapeutics Inc | 0.52% | $5.20M |
| Alumis Inc | 0.50% | $4.99M |
| Enliven Therapeutics Inc | 0.49% | $4.88M |
| Innoviva, Inc. | 0.46% | $4.63M |
| Organon & Co. | 0.43% | $4.35M |
| Perrigo Company Public Limited Company | 0.41% | $4.13M |
| Ocular Therapeutix, Inc. | 0.41% | $4.12M |
| Ani Pharmaceuticals, Inc. | 0.39% | $3.86M |
| Trevi Therapeutics Inc | 0.35% | $3.46M |
| Harrow, Inc. | 0.32% | $3.25M |
| Amylyx Pharmaceuticals Inc | 0.32% | $3.24M |
| Phibro Animal Health Corporation | 0.32% | $3.19M |
| Harmony Biosciences Holdings, Inc. | 0.31% | $3.11M |
| WAVE Life Sciences Ltd | 0.29% | $2.93M |
| Collegium Pharmaceutical, Inc. | 0.29% | $2.92M |
| Nuvation Bio Inc | 0.29% | $2.87M |
| Eyepoint, Inc. | 0.28% | $2.80M |
| Xeris Biopharma Holdings, Inc. | 0.27% | $2.69M |
| Pacira Biosciences, Inc. | 0.26% | $2.59M |
| Rapport Therapeutics Inc | 0.25% | $2.50M |
| MBX Biosciences Inc | 0.21% | $2.10M |
| Omeros Corporation | 0.21% | $2.09M |
| Amphastar Pharmaceuticals, Inc. | 0.19% | $1.94M |
| Arvinas Inc | 0.19% | $1.90M |
| Maze Therapeutics Inc | 0.18% | $1.77M |
| Theravance Biopharma, Inc. | 0.17% | $1.68M |
| LB Pharmaceuticals Inc | 0.17% | $1.68M |
| Phathom Pharmaceuticals, Inc. | 0.15% | $1.55M |
| Septerna Inc | 0.15% | $1.53M |
| BIOAGE Labs Inc | 0.15% | $1.47M |
| Cormedix Inc. | 0.14% | $1.39M |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency Shares | 0.09% | $901.59K |
| Evolus Inc | 0.07% | $744.61K |
| LENZ Therapeutics Inc | 0.06% | $560.15K |
| Xav Health Care Jun26 | -0.00% | $-33.49K |